What’s new

• Signed five-year, non-exclusive licence for wheat variety HUW 838 from BHU.
• Gets rights to produce foundation, certified and truthfully labelled seed.
• BHU retains breeder rights; deal renewable by mutual consent.

Why it matters

For a nano-cap with just ₹1 cr quarterly profit, a formal partnership with BHU is a strategic validation. It opens a real revenue stream in seed commercialisation, even without exclusivity. The deal lifts the company's profile from trader to licensed producer of a named variety.

What we’re watching

• Whether the company can scale seed production and distribution to rural markets.
• Any follow-on licensing deals with other institutes or government agencies.
• Revenue contribution from seed sales in the next two quarters.

The full read

MRC Agrotech, a nano-cap with a ₹115 cr market cap, has signed a five-year non-exclusive licence with Banaras Hindu University for wheat variety HUW 838. The deal lets the company produce foundation, certified and truthfully labelled seed. BHU keeps breeder rights; the pact is renewable. For a company that reported just ₹1 cr net profit in its latest quarter, this deal is a strategic step that adds credibility and a genuine revenue stream beyond trading, even if the non-exclusive structure and undisclosed finances limit immediate quantification. Not a knockout. Prior concerns about revenue concentration in March (45% of FY26 sales) still hover. But this deal gives the market something new to focus on.

Primary source: BSE · NSE

What’s new

• Board meeting on 22 June 2026 to consider two proposals.
• Conversion of ₹3.88 cr loans into equity in 51% owned subsidiary.
• Lease of approx 50 acres for operational requirements.

Why it matters

The proposals could reshape the subsidiary's capital structure and MRC's operational footprint. Coming just weeks after auditor flagged half of FY26 revenue recognized in March, scrutiny will fall on the terms of any related-party transaction.

What we’re watching

• Final decision and valuation of loan conversion.
• Lease terms and counterparty details.
• Any impact on minority stake in subsidiary.

The full read

MRC Agrotech's board will meet on 22 June 2026 to consider two proposals: converting ₹3.88 crore of loans into equity in its 51% owned subsidiary, and leasing 50 acres of land for operations. Both are potentially material for a company capitalised at just ₹111 crore and whose auditor recently flagged that 44.6% of taxable supplies were recognised in March alone. The open question is the board's decision on terms and pricing. Until then, this is an agenda, not a verdict.

Primary source: BSE · NSE

What’s new

• Standalone revenue more than doubled to ₹85.46 crore in FY26 from ₹32.45 crore a year earlier.
• The auditor flagged that 44.6% of taxable supplies were booked in the final month.
• Two related counterparties accounted for 53% of total purchases.

Why it matters

The auditor's emphasis-of-matter paragraphs reframe the top-line surge. When nearly half of a year's sales land in March and just two suppliers represent over half of purchases, the growth looks less like a business win and more like a timing event.

What we’re watching

• Whether the March sales concentration repeats in FY27.
• If the two dominant suppliers remain in the mix.
• How the share-swap acquisition of Marsapi Lifesciences performs.

The full read

MRC Agrotech's revenue more than doubled to ₹85.46 crore in FY26. Profit grew too, to ₹1.17 crore from ₹0.88 crore, but the gain is modest against that scale-up. The real story is in the auditor's report. 44.6% of the year's taxable supplies were booked in March. And 53% of purchases went to just two suppliers, who are related to each other. The filing also incorporates the share-swap acquisition of Marsapi Lifesciences, a deal done without cash. For a company with a ₹32.45 crore revenue base just a year ago, the growth is real. The auditor's warnings about concentration in both sales and purchases suggest the foundation is not. Hardly. The growth looks like a single-month event.

Primary source: BSE · NSE

What’s new

• FY26 standalone revenue surged 163% to ₹85.45 crore from ₹32.44 crore a year earlier.
• The auditor flagged that 45% of total revenue was recognised in the final month of the fiscal year.
• Two related counterparties accounted for 53% of all purchases, and a ₹16.85 cr Marsapi Lifesciences acquisition was consolidated.

Why it matters

The 163% headline growth is undermined by its timing and concentration. Bunching nearly half of the year's revenue into March raises questions about its sustainability and the quality of earnings. For a nano-cap firm, relying this heavily on two related counterparties adds significant operational and related-party risk to the balance sheet.

What we’re watching

• Whether Q1 FY27 revenue sustains the pace or normalises after the March spike.
• Any follow-up on the delayed statutory filing and audit reconciliation issues.
• The performance integration of the newly consolidated Marsapi Lifesciences.

The full read

Revenue tripled. Profit turned positive. MRC Agrotech's FY26 numbers look spectacular on the surface, with standalone revenue soaring 163% to ₹85.45 crore and net profit hitting ₹1.16 crore. The audit report tells a different story. 45% of that revenue arrived in March alone. 53% of purchases came from two related counterparties. The company also consolidated a ₹16.85 crore non-cash acquisition of Marsapi Lifesciences. For a nano-cap agri-trader, the growth is real on paper. Its composition is not. The missed filing deadline, blamed on reconciling high-volume trading, doesn't inspire confidence in the underlying controls.

Primary source: BSE · NSE

What’s new

• MRC Agrotech is delaying its FY26 audited annual results past the May 30 deadline.
• The company says auditors require more time for year-end reconciliations.
• A board meeting is scheduled for the first week of June to approve the figures.

Why it matters

Missing a statutory filing deadline is a major red flag for a company with a ₹120 crore market cap. It creates immediate uncertainty about the quality of the books and increases the risk of regulatory scrutiny.

What we’re watching

• The new date for the board meeting to approve the financial statements.
• Any potential regulatory queries from the exchange.
• The quality of the final audit report when it eventually surfaces.

The full read

MRC Agrotech will not meet the May 30 statutory deadline for its FY26 audited results.

The company claims the delay stems from ongoing audit procedures and year-end reconciliations that remain unfinished.

The board is now expected to meet during the first week of June to address the financials. For a ₹120 crore nano-cap firm, this type of delay rarely stays procedural. It invites exchange queries and raises questions about potential accounting friction between the auditor and management.

Investors are left waiting to see if these reconciliations are truly routine or if they precede more significant reporting issues that the market has yet to fully appreciate. Silence is dangerous.

Primary source: BSE · NSE